Acerca de Qlaris bio, inc.

Acerca de la compañía

Qlaris Bio focuses on developing novel and innovative therapies for serious and debilitating ophthalmic diseases. Qlaris Bio is a spinout company of Qrativ, a biotechnology incubator formed as a joint venture between Mayo Clinic and inference, a pharmaceutical-focused artificial intelligence company. Its lead program is QLS-101, a novel compound invented at Mayo Clinic and the University of Minnesota. QLS-101, with its unique and first-in-class mechanism of action, may potentially serve as an efficacious treatment for high unmet need conditions related to disturbances in intraocular pressure, including a sight-threatening and progressive Pediatric Rare Disease for which effective therapies remain elusive and limited. Qlaris Bio was founded in 2019 and is headquartered in Cambridge, Massachusetts.